ReviewFrontiers in immunology2026
Immune checkpoint inhibitor-associated diabetes mellitus: an overlooked immune-related adverse event-two case reports and a literature review.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitor-associated diabetes mellitus (ICI-DM) is a relatively uncommon manifestation of immune-related adverse events. However, it often presents with diabetic ketoacidosis (DKA) at onset, which may lead to severe and potentially life-threatening complications. Therefore, early recognition and treatment are essential. This condition typically occurs within the first three months after initiation of immunotherapy, whereas delayed onset after treatment discontinuation has been infrequently reported. In this study, Case 1 developed diabetic ketoacidosis 9 weeks after discontinuation of serplulimab (approximately 19 months after treatment initiation), representing a rare delayed-onset presentation. Case 2 developed hyperglycemia after 23 weeks of envafolimab therapy and exhibited preserved islet function without DKA, suggesting a possible early-stage or type 2 diabetes-like phenotype of ICI-related dysglycemia. Both patients achieved glycemic control with exogenous insulin therapy. Immunotherapy was discontinued in Case 1, whereas Case 2 continued treatment with satisfactory glycemic control. This study summarizes the pathogenesis, clinical characteristics, management, and prognosis of ICI-DM, highlighting its heterogeneity and the importance of early detection of ICI-related dysglycemia. Early and continuous glucose monitoring during and after immunotherapy is essential, and ongoing follow-up after treatment discontinuation remains warranted.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.